Why Gilead's COVID Drug May Be The Magic Bullet We
Post# of 123679
Summary
GILD surged to $84 Friday on the leak that University of Chicago Medicine's head researcher in GILD COVID studies reported that GILD's RDV (remdesivir) worked well.
The data that Dr. Mullane reported to her colleagues suggests that RDV could be a "magic bullet," honing in on the coronavirus and destroying it quickly.
This report is consistent with a relatively small but internally consistent group of positive reports about RDV.
I liked GILD under the new CEO, Dan O'Day, before COVID, and think that RDV could be a valuable catalyst in GILD's longer term resurgence toward sustained growth.
If RDV meets the high hopes some now have for it, I also believe it could be a material factor in allowing the economy and markets to heal, and for lockdowns to vanish.
Whole story>>>>>
https://seekingalpha.com/article/4338423-why-...ent=link-0